{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:37:21Z","timestamp":1768261041831,"version":"3.49.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.tox.2022.153341","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T13:01:25Z","timestamp":1664542885000},"page":"153341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The immunology of botulinum toxin therapy: A brief summary"],"prefix":"10.1016","volume":"481","author":[{"given":"Dirk","family":"Dressler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Bigalke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Frevert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2022.153341_bib1","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1212\/WNL.0000000000006688","article-title":"High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy","volume":"92","author":"Albrecht","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.tox.2022.153341_bib2","series-title":"Scientific and Therapeutic Aspects of Botulinum Toxin","first-page":"103","article-title":"Immunological and other properties of therapeutic botulinum toxin serotypes","author":"Aoki","year":"2002"},{"key":"10.1016\/j.tox.2022.153341_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/toxins11090491","article-title":"Immunogenicity Associated with Botulinum ToxinTreatment","volume":"11","author":"Bellows","year":"2019","journal-title":"Toxins"},{"key":"10.1016\/j.tox.2022.153341_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12640-017-9737-6","article-title":"Long-term abobotulinumtoxin a treatment of cervical dystonia","volume":"32","author":"Bentivoglio","year":"2017","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.tox.2022.153341_bib5","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.3390\/toxins7124855","article-title":"Botulinum neurotoxins: qualitative and quantitative analysis using the mouse phrenic nerve hemidiaphragm assay (MPN)","volume":"7","author":"Bigalke","year":"2015","journal-title":"Toxins"},{"key":"10.1016\/j.tox.2022.153341_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000082567","article-title":"Systemic immediate allergic reactions to arthropod stings and bites","volume":"210","author":"Bircher","year":"2005","journal-title":"Dermatol"},{"key":"10.1016\/j.tox.2022.153341_bib7","first-page":"238","article-title":"Comparative antigenicity of botulinum neurotoxin type A in the rabbit. [abstract]","volume":"9","author":"Bluemel","year":"2006","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.tox.2022.153341_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/1744666X.2018.1468753","article-title":"Immunogenicity of biologic therapies: causes and consequences","volume":"14","author":"Boehncke","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.tox.2022.153341_bib9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tox.2022.153341_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clindermatol.2003.12.027","article-title":"Botulinum toxin type B (Myobloc\u00ae): pharmacology and biochemistry","volume":"22","author":"Callaway","year":"2004","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.tox.2022.153341_bib11","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/DSS.0000000000001206","article-title":"Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo","volume":"43","author":"Carruthers","year":"2017","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.tox.2022.153341_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1089\/vim.2006.19.54","article-title":"Ricin toxin B subunit enhancement of rotavirus NSP4 immunogenicity in mice","volume":"19","author":"Choi","year":"2006","journal-title":"Viral Immunol."},{"issue":"Suppl","key":"10.1016\/j.tox.2022.153341_bib13","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1097\/00002508-200211001-00004","article-title":"Considering the immune response to botulinum toxin","volume":"18","author":"Critchfield","year":"2002","journal-title":"Clin. J. Pain."},{"issue":"Suppl 8","key":"10.1016\/j.tox.2022.153341_bib14","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1002\/mds.20022","article-title":"Clinical presentation and management of antibody-induced failure of botulinum toxin therapy","volume":"19","author":"Dressler","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tox.2022.153341_bib15","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s00115-006-2090-2","article-title":"Pharmacological aspects of therapeutic botulinum toxin preparations","volume":"77","author":"Dressler","year":"2006","journal-title":"Nervenarzt"},{"key":"10.1016\/j.tox.2022.153341_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/mds.1238","article-title":"Botulinum toxin antibody titres after cessation of botulinum toxin therapy","volume":"17","author":"Dressler","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tox.2022.153341_bib17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s00415-005-0774-3","article-title":"Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure","volume":"252","author":"Dressler","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.tox.2022.153341_bib18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14737175.2017.1262258","article-title":"Immunological aspects of botulinum toxin therapy","volume":"17","author":"Dressler","year":"2017","journal-title":"Exp. Rev. Neurother."},{"issue":"suppl 2","key":"10.1016\/j.tox.2022.153341_bib19","article-title":"Botulinum toxin therapy: risk factors for therapy failure","volume":"15","author":"Dressler","year":"2000","journal-title":"Mov. Disord."},{"issue":"Suppl 1","key":"10.1016\/j.tox.2022.153341_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2006.01439.x","article-title":"Immunological aspects of Botox\u00ae, Dysport\u00ae and Myobloc\u00ae\/NeuroBloc\u00ae","volume":"13","author":"Dressler","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.tox.2022.153341_bib21","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s004150070132","article-title":"The sternocleidomastoid test: an in vivo assay to inestigate botulinum toxin antibody formation in humans","volume":"247","author":"Dressler","year":"2000","journal-title":"J. Neurol."},{"key":"10.1016\/j.tox.2022.153341_bib22","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/mds.20625","article-title":"The mouse diaphragm assay for detection of antibodies against botulinum toxin type B","volume":"20","author":"Dressler","year":"2005","journal-title":"Mov. Disord."},{"issue":"Suppl 4","key":"10.1016\/j.tox.2022.153341_bib23","first-page":"2182","article-title":"Antibody-induced botulinum toxin therapy failure in dermal indications","volume":"36","author":"Dressler","year":"2011","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.tox.2022.153341_bib24","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/mds.25956","article-title":"An enzyme-linked immunosorbent assay for detection of botulinumtoxin-antibodies","volume":"29","author":"Dressler","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tox.2022.153341_bib25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00702-014-1253-8","article-title":"Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects","volume":"122","author":"Dressler","year":"2015","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.tox.2022.153341_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00702-014-1253-8","article-title":"Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects","volume":"122","author":"Dressler","year":"2015","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.tox.2022.153341_bib27","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00702-018-1911-3","article-title":"Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity","volume":"125","author":"Dressler","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.tox.2022.153341_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12640-015-9565-5","article-title":"Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis","volume":"29","author":"Fabbri","year":"2016","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.tox.2022.153341_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","article-title":"Content of botulinum neurotoxin in Botox\u00ae\/Vistabel\u00ae, Dysport\u00ae\/Azzalure\u00ae, and Xeomin\u00ae\/Bocouture\u00ae","volume":"10","author":"Frevert","year":"2010","journal-title":"Drugs R. D."},{"key":"10.1016\/j.tox.2022.153341_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","article-title":"Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences","volume":"147","author":"Goeschel","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.tox.2022.153341_bib31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","article-title":"Development of resistance to botulinum toxin type A in patients with torticollis","volume":"9","author":"Greene","year":"1994","journal-title":"Mov. Disord."},{"issue":"6071","key":"10.1016\/j.tox.2022.153341_bib32","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1126\/science.1214270","article-title":"Botulinum Neurotoxin is Shielded by NTNHA in an interlocked complex","volume":"335","author":"Gu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.tox.2022.153341_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.172","article-title":"Bacterial flagellin-a potent immunomodulatory agent","volume":"49","author":"Hajam","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.tox.2022.153341_bib34","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1128\/IAI.74.2.1113-1120.2006","article-title":"Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis","volume":"74","author":"Honko","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tox.2022.153341_bib35","unstructured":"Hunt T.J. (2007) Botulinum toxin composition. US Patent application 2007\/0025019."},{"key":"10.1016\/j.tox.2022.153341_bib36","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","article-title":"Response and immunoresistance to botulinum toxin injections","volume":"45","author":"Jankovic","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.tox.2022.153341_bib37","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.tox.2022.153341_bib38","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00415-019-09349-2","article-title":"Treatment of cervical dystonia with abo- and onabotulinumtoxin A: long-term safety and efficacy in daily clinical practice","volume":"266","author":"Jochim","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.tox.2022.153341_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.870120116","article-title":"The EDB test-a clinical test for the detection of antibodies to botulinum toxin type A","volume":"12","author":"Kessler","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tox.2022.153341_bib40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","article-title":"Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group","volume":"246","author":"Kessler","year":"1999","journal-title":"J. Neurol."},{"key":"10.1016\/j.tox.2022.153341_bib41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1196\/annals.1313.027","article-title":"Related Articles Antibodies against erythropoietin and other protein-based therapeutics: an overview","volume":"1050","author":"Kromminga","year":"2005","journal-title":"Ann. N. Y Acad. Sci."},{"key":"10.1016\/j.tox.2022.153341_bib42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","article-title":"Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?","volume":"32","author":"Lange","year":"2009","journal-title":"Clin. Neuropharmacol"},{"key":"10.1016\/j.tox.2022.153341_bib43","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1099\/mic.0.28421-0","article-title":"Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin","volume":"151","author":"Lee","year":"2005","journal-title":"Microbiol"},{"key":"10.1016\/j.tox.2022.153341_bib44","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1128\/IAI.74.1.694-702.2006","article-title":"A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity","volume":"74","author":"Lee","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tox.2022.153341_bib45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-1-0716-0430-4_20","article-title":"Functional analysis of botulinum hemagglutinin (HA)","volume":"2132","author":"Matsumura","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tox.2022.153341_bib46","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-009-0223-z","article-title":"Prevalence of neutralizing antibodies in patients treated with botulinum toxin type A for spasticity","volume":"116","author":"Mueller","year":"2009","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.tox.2022.153341_bib47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jneuroim.2011.06.005","article-title":"Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients","volume":"237","author":"Oshima","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tox.2022.153341_bib48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1504\/TBJ.2008.018956","article-title":"Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use","volume":"1","author":"Panjwani","year":"2008","journal-title":"Botulinum J."},{"key":"10.1016\/j.tox.2022.153341_bib49","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/archneur.63.12.1808","article-title":"Neutralizing antibodies against botulinum toxin a after a wasp sting","volume":"63","author":"Paus","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.tox.2022.153341_bib50","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.toxicon.2018.11.227","article-title":"Nonclinical overview of daxibotulinumtoxinA for injection to support registration for human use","volume":"156","author":"Prawdzik","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.tox.2022.153341_bib51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/asj\/sjab058","article-title":"Immunogenicity to botulinum toxin type A: A systematic review with meta-analysis across therapeutic indications","volume":"42","author":"Rahman","year":"2022","journal-title":"Aesthet. Surg. J."},{"key":"10.1016\/j.tox.2022.153341_bib52","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.toxicon.2011.04.003","article-title":"Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies","volume":"57","author":"Rasetti-Escargueil","year":"2011","journal-title":"Toxicon"},{"key":"10.1016\/j.tox.2022.153341_bib53","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.2174\/1389201020666190716110705","article-title":"Plant phenolics and lectins as vaccine adjuvants","volume":"20","author":"Reyna-Margarita","year":"2019","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.tox.2022.153341_bib54","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nbt1303","article-title":"A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs","volume":"25","author":"Shankar","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tox.2022.153341_bib55","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1128\/jcm.27.8.1906-1908.1989","article-title":"Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid","volume":"27","author":"Siegel","year":"1989","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.tox.2022.153341_bib56","article-title":"Development of inhibition ELISA to detect antibody-induced failure of botulinum toxin a therapy in cosmetic indications","volume":"473","author":"Srinoulprasert","year":"2019","journal-title":"J. Immunol. Methods, Oct."},{"issue":"586","key":"10.1016\/j.tox.2022.153341_bib57","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.febslet.2011.12.037","article-title":"Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity","volume":"17","author":"Strotmeier","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tox.2022.153341_bib58","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/mds.20073","article-title":"Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A","volume":"19","author":"Voller","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tox.2022.153341_bib59","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/PL00004951","article-title":"Botulinum A toxins: units versus units","volume":"355","author":"Wohlfarth","year":"1997","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharm."},{"key":"10.1016\/j.tox.2022.153341_bib60","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s12640-021-00378-2","article-title":"Botulinum injections for idiopathic cervical dystonia: a longitudinal study","volume":"39","author":"Yahalom","year":"2021","journal-title":"Neurotox. Res."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X22002530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X22002530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:52:13Z","timestamp":1759535533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X22002530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":60,"alternative-id":["S0300483X22002530"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2022.153341","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunology of botulinum toxin therapy: A brief summary","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2022.153341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"153341"}}